Immunomodulating Drugs Based on Poxviral Proteins

[1]  S. Shchelkunov,et al.  TNF-Binding domain of the variola virus CrmB protein synthesized in Escherichia coli cells effectively interacts with human TNF , 2015, Doklady Biochemistry and Biophysics.

[2]  S. Shchelkunov,et al.  TNF binding protein of variola virus acts as a TNF antagonist at epicutaneous application. , 2015, Current pharmaceutical biotechnology.

[3]  J. Shisler.  Immune evasion strategies of molluscum contagiosum virus. , 2015, Advances in virus research.

[4]  S. Shchelkunov,et al.  Exploring Interaction of TNF and Orthopoxviral CrmB Protein by Surface Plasmon Resonance and Free Energy Calculation , 2014, Protein and peptide letters.

[5]  Дондок Дамдинович Цырендоржиев,et al.  EFFICIENCY OF RECOMBINANT TNF-BINDING PROTEIN FROM VARIOLA VIRUS IN A MODEL OF COLLAGEN-INDUCED ARTHRITIS , 2014 .

[6]  S. Shchelkunov,et al.  Biological Effects of Individually Synthesized TNF-Binding Domain of Variola Virus CrmB Protein , 2014, Bulletin of Experimental Biology and Medicine.

[7]  L. Czirják,et al.  Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison , 2014, The European Journal of Health Economics.

[8]  C. Maluquer de Motes,et al.  Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. , 2013, The Journal of general virology.

[9]  D. Greaves,et al.  CC Chemokine Receptors and Chronic Inflammation—Therapeutic Opportunities and Pharmacological Challenges , 2013, Pharmacological Reviews.

[10]  D. Fremont,et al.  Subversion of cytokine networks by virally encoded decoy receptors , 2012, Immunological reviews.

[11]  S. Shchelkunov.  Orthopoxvirus Genes That Mediate Disease Virulence and Host Tropism , 2012, Advances in virology.

[12]  G. Keating,et al.  Spotlight on Etanercept in Rheumatoid Arthritis, Psoriatic Arthritis and Juvenile Rheumatoid Arthritis , 2012, BioDrugs.

[13]  Aizhi Zhao,et al.  Modulation of immune and inflammatory responses on experimental arthritis following intraarticular gene transfer of tumor necrosis factor receptor-immunoglobulin Fc , 2012, Rheumatology International.

[14]  S. Shchelkunov.  Emergence and reemergence of smallpox: the need for development of a new generation smallpox vaccine. , 2011, Vaccine.

[15]  G. Oderda,et al.  Managed Care Strategies for Improving Patient Outcomes in Rheumatoid Arthritis , 2011 .

[16]  D. Greaves,et al.  Site-Directed Mutagenesis of the CC Chemokine Binding Protein 35K-Fc Reveals Residues Essential for Activity and Mutations That Increase the Potency of CC Chemokine Blockade , 2011, Molecular Pharmacology.

[17]  G. McFadden,et al.  Viral serpin therapeutics from concept to clinic. , 2011, Methods in enzymology.

[18]  S. Shchelkunov,et al.  Orthopoxviruses Pathogenic for Humans , 2010 .

[19]  J. Tardif,et al.  A Randomized Controlled, Phase 2 Trial of the Viral Serpin Serp-1 in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention , 2010, Circulation. Cardiovascular interventions.

[20]  S. Shchelkunov,et al.  SECRET domain of variola virus CrmB protein can be a member of poxviral type II chemokine-binding proteins family , 2010, BMC Research Notes.

[21]  S. Shchelkunov.  Interaction of orthopoxviruses with the cellular ubiquitin-ligase system , 2010, Virus Genes.

[22]  A. Alcamí,et al.  Modulation of chemokine activity by viruses. , 2010, Current opinion in immunology.

[23]  G. McFadden,et al.  Inhibition of Chemokine-Glycosaminoglycan Interactions in Donor Tissue Reduces Mouse Allograft Vasculopathy and Transplant Rejection , 2010, PloS one.

[24]  K. Dao,et al.  Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study , 2010, The Journal of Rheumatology.

[25]  S. Shchelkunov,et al.  Recombinant TNF-binding protein from variola virus as a novel potential TNF antagonist , 2009, Biochemistry (Moscow).

[26]  S. Shchelkunov.  How long ago did smallpox virus emerge? , 2009, Archives of Virology.

[27]  G. McFadden,et al.  Viral TNF inhibitors as potential therapeutics. , 2009, Advances in experimental medicine and biology.

[28]  D. Paterson,et al.  Lentiviral gene transfer to reduce atherosclerosis progression by long-term CC-chemokine inhibition , 2009, Gene Therapy.

[29]  G. Kotwal,et al.  Vaccinia complement control protein: Multi-functional protein and a potential wonder drug , 2003, Journal of Biosciences.

[30]  Wuding Zhou,et al.  The relative importance of local and systemic complement production in ischaemia, transplantation and other pathologies. , 2007, Molecular immunology.

[31]  John D Lambris,et al.  The role of complement in inflammatory diseases from behind the scenes into the spotlight. , 2007, The American journal of pathology.

[32]  L. Kellaway,et al.  Vaccinia virus complement control protein significantly improves sensorimotor function recovery after severe head trauma , 2007, Brain Research.

[33]  D. Greaves,et al.  Membrane-Bound CC Chemokine Inhibitor 35K Provides Localized Inhibition of CC Chemokine Activity In Vitro and In Vivo1 , 2006, The Journal of Immunology.

[34]  S. Shchelkunov,et al.  Properties of the recombinant TNF-binding proteins from variola, monkeypox, and cowpox viruses are different , 2006, Biochimica et biophysica acta.

[35]  R. Buller,et al.  The Unique C Termini of Orthopoxvirus Gamma Interferon Binding Proteins Are Essential for Ligand Binding , 2006, Journal of Virology.

[36]  Margarida Saraiva,et al.  A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Atkinson,et al.  Structure and Regulatory Profile of the Monkeypox Inhibitor of Complement: Comparison to Homologs in Vaccinia and Variola and Evidence for Dimer Formation1 , 2006, The Journal of Immunology.

[38]  J. Braun,et al.  Anti-TNF-α agents in the treatment of psoriatic arthritis , 2006 .

[39]  J. Braun,et al.  Anti-TNF-alpha agents in the treatment of psoriatic arthritis. , 2006, Expert opinion on biological therapy.

[40]  E. Gunnarsson,et al.  Vaccinia Virus Complement Control Protein Diminishes Formation of Atherosclerotic Lesions: Complement Is Centrally Involved in Atherosclerotic Disease , 2005, Annals of the New York Academy of Sciences.

[41]  G. Kotwal,et al.  Humanized Recombinant Vaccinia Virus Complement Control Protein (hrVCP) with Three Amino Acid Changes, H98Y, E102K, and E120K Creating an Additional Putative Heparin Binding Site, Is 100‐fold More Active Than rVCP in Blocking Both Classical and Alternative Complement Pathways , 2005, Annals of the New York Academy of Sciences.

[42]  L. Kellaway,et al.  Administration of Vaccinia Virus Complement Control Protein Shows Significant Cognitive Improvement in a Mild Injury Model , 2005, Annals of the New York Academy of Sciences.

[43]  S. Shchelkunov,et al.  Comparison of the Interferon γ-Binding Proteins of the Variola and Monkeypox Viruses , 2005, Molecular Biology.

[44]  M. Harmsen,et al.  Viral chemokine-modulatory proteins: tools and targets. , 2005, Cytokine & growth factor reviews.

[45]  S. Shchelkunov.  Functional organization of variola major and vaccinia virus genomes , 2005, Virus Genes.

[46]  D. Lahiri,et al.  Vaccinia Virus Complement Control Protein Reduces Inflammation and Improves Spinal Cord Integrity Following Spinal Cord Injury , 2004, Annals of the New York Academy of Sciences.

[47]  D. Greaves,et al.  Broad-Spectrum CC-Chemokine Blockade by Gene Transfer Inhibits Macrophage Recruitment and Atherosclerotic Plaque Formation in Apolipoprotein E–Knockout Mice , 2004, Circulation.

[48]  Alexandra Lucas,et al.  Secreted Immunomodulatory Viral Proteins as Novel Biotherapeutics12 , 2004, The Journal of Immunology.

[49]  G. McFadden,et al.  VIRAL CHEMOKINE-BINDING PROTEINS INHIBIT INFLAMMATORY RESPONSES AND AORTIC ALLOGRAFT TRANSPLANT VASCULOPATHY IN RAT MODELS , 2004, Transplantation.

[50]  G. Kotwal,et al.  Vaccinia Virus Complement Control Protein Modulates Inflammation Following Spinal Cord Injury , 2003, Annals of the New York Academy of Sciences.

[51]  G. McFadden,et al.  Poxviruses and immune evasion. , 2003, Annual review of immunology.

[52]  G. McFadden,et al.  CHEMOKINE‐BINDING VIRAL PROTEIN M‐T7 PREVENTS CHRONIC REJECTION IN RAT RENAL ALLOGRAFTS , 2003, Transplantation.

[53]  Scott A. Smith,et al.  Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation. , 2003, Transplant immunology.

[54]  M. Lindow,et al.  Viral leads for chemokine-modulatory drugs. , 2003, Trends in pharmacological sciences.

[55]  G. Kotwal,et al.  Vaccinia virus complement control protein ameliorates hyperacute xenorejection by inhibiting xenoantibody binding. , 2002, Transplantation proceedings.

[56]  T. Giese,et al.  Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease , 2002, Virchows Archiv.

[57]  E. A. Uvarova,et al.  Analysis of the Monkeypox Virus Genome , 2002, Virology.

[58]  Zhiping Nie,et al.  Variola virus immune evasion design: Expression of a highly efficient inhibitor of human complement , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[59]  A. Alcamí,et al.  Inhibition of Interferons by Ectromelia Virus , 2002, Journal of Virology.

[60]  E. A. Uvarova,et al.  Species-specific differences in the structure of orthopoxvirus complement-binding protein , 2001, Virus research.

[61]  O. Favorova,et al.  Randomized study of antibodies to IFN-g and TNF-a in secondary progressive multiple sclerosis , 2001 .

[62]  B. Rollins,et al.  Chemokines and disease , 2001, Nature Immunology.

[63]  O. Favorova,et al.  Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. , 2001, Multiple sclerosis.

[64]  T. Schaible,et al.  Anti – Tumor Necrosis Factor Therapies In Crohn’s Disease And Rheumatoid Arthritis , 2000 .

[65]  D. Liggitt,et al.  Local Blockade of Allergic Airway Hyperreactivity and Inflammation by the Poxvirus-Derived Pan-CC-Chemokine Inhibitor vCCI1 , 2000, The Journal of Immunology.

[66]  A. Alcamí,et al.  Viral mechanisms of immune evasion , 2000, Immunology Today.

[67]  S. Shchelkunov,et al.  Conserved Surface-Exposed K/R-X-K/R Motifs and Net Positive Charge on Poxvirus Complement Control Proteins Serve as Putative Heparin Binding Sites and Contribute to Inhibition of Molecular Interactions with Human Endothelial Cells: a Novel Mechanism for Evasion of Host Defense , 2000, Journal of Virology.

[68]  G. McFadden,et al.  The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury. , 2000, The Journal of clinical investigation.

[69]  R. Hoffmann,et al.  The potential role of cytokines and T cells in alopecia areata. , 1999, The journal of investigative dermatology. Symposium proceedings.

[70]  K. Asadullah,et al.  The pathophysiological role of cytokines in psoriasis. , 1999, Drugs of today.

[71]  S. Azar,et al.  T Helper Type 1 and 2 Cytokines Mediate the Onset and Progression of Type I (Insulin-Dependent) Diabetes , 1999 .

[72]  C. Sotozono,et al.  Cytokine expression during orthotopic corneal allograft rejection in mice. , 1998, Investigative ophthalmology & visual science.

[73]  S. Shchelkunov,et al.  The genomic sequence analysis of the left and right species-specific terminal region of a cowpox virus strain reveals unique sequences and a cluster of intact ORFs for immunomodulatory and host range proteins. , 1998, Virology.

[74]  J. Atkinson,et al.  Novel complement inhibitors. , 1998, Expert opinion on investigational drugs.

[75]  S. Skurkovich,et al.  Successful first-time use of antibodies to interferon-γ alone and combined with antibodies to tumor necrosis factor-α to treat rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, Behcet's syndrome) , 1998 .

[76]  G. McFadden,et al.  The purified myxoma virus gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines , 1997, Journal of virology.

[77]  S. Shchelkunov,et al.  The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein. , 1997, Virology.

[78]  E. Keystone,et al.  Expression of interferon‐gamma (IFN‐δ), IL‐10, IL‐12 and transforming growth factor‐beta (TGF‐β) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA) , 1996, Clinical and experimental immunology.

[79]  A. Alcamí,et al.  Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity , 1995, Journal of virology.

[80]  B. Moss,et al.  Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins , 1988, Nature.